×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
ETR:SAZ

STADA Arzneimittel Aktiengesellschaft Stock Forecast, Price & News

€80.40
0.00 (0.00%)
(As of 11/27/2018)
Add
Compare
Today's Range
€79.56
€80.98
50-Day Range
€80.40
€80.40
52-Week Range
€53.41
€80.98
Volume
92,068 shs
Average Volume
51,761 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

STADA Arzneimittel Aktiengesellschaft MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.22 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive SAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

STADA Arzneimittel Aktiengesellschaft logo

About STADA Arzneimittel Aktiengesellschaft (ETR:SAZ) Stock

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

SAZ Stock News Headlines

STADA agreement extended for the Nordic Region
See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A














STADA Arzneimittel Aktiengesellschaft Frequently Asked Questions

How has STADA Arzneimittel Aktiengesellschaft's stock performed in 2022?

STADA Arzneimittel Aktiengesellschaft's stock was trading at €80.40 on January 1st, 2022. Since then, SAZ stock has increased by 0.0% and is now trading at €80.40.
View the best growth stocks for 2022 here
.

Who are STADA Arzneimittel Aktiengesellschaft's key executives?

STADA Arzneimittel Aktiengesellschaft's management team includes the following people:
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 54)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 53)
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)
  • Ms. Kay Reubelt, Director of Investor Relations

What other stocks do shareholders of STADA Arzneimittel Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STADA Arzneimittel Aktiengesellschaft investors own include ProSiebenSat.1 Media (PSM), Renault (RNO), Sarepta Therapeutics (SRPT), Volkswagen Aktiengesellschaft (VLKAY), Volkswagen (VOW3), ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), Andersons (ANDE) and ANI Pharmaceuticals (ANIP).

What is STADA Arzneimittel Aktiengesellschaft's stock symbol?

STADA Arzneimittel Aktiengesellschaft trades on the ETR under the ticker symbol "SAZ."

What is STADA Arzneimittel Aktiengesellschaft's stock price today?

One share of SAZ stock can currently be purchased for approximately €80.40.

How can I contact STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft's mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.de. The company can be reached via phone at +49-6101-6030.

This page (ETR:SAZ) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.